Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 3Thoracic 3Sarcoma 3Other solid neoplasm 3CNS 3Breast 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Gastrointestinal 2Endocrine 2Dermatologic 2NET 1Lymphoid 1Gynecologic 1Classical hematology 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Carcinoma 1Adenocarcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × vatalanib × Tumor-Agnostic × Clear all
NCT00731861 2014-09-11

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

Indiana University

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT00226005 2012-05-09

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer Research Team

Phase 2 Completed
67 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT00611793 2009-01-23

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

SCRI Development Innovations, LLC

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡